A Study to Investigate Efficacy and Safety of OG-6219 (17betaHSD1 inhibitor) in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain (ELENA). Here, HSD17B1 is linked to endometriosis.